Different vascular healing process between bioabsorbable polymer-coated everolimus-eluting stents versus bioresorbable vascular scaffolds via optical coherence tomography and coronary angioscopy (the ENHANCE study: ENdothelial Healing Assessment with Novel Coronary tEchnology)
Authors:
Open Access
- 5 October 2019
- journal article
- research article
- Published by Springer Nature in Heart and Vessels
- Vol. 35 (4) , 463-473
Abstract
Recent clinical trials have raised concerns about the safety and efficacy of ABSORB™ bioresorbable vascular scaffolds (BVS). The difference in the vascular healing process between SYNERGY™ bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) and BVS remains unclear. The aim of the ENHANCE study was to compare vascular healing on BP-EES versus BVS by optical coherence tomography (OCT) and coronary angioscopy (CAS) at 4- and 12-month follow-ups. This is a prospective, non-randomized, single center clinical trial. Thirteen eligible patients with multivessel disease were enrolled. BP-EES and BVS were simultaneously implanted in the same patients, but in different coronary vessels. Imaging follow-up with both OCT and CAS was completed in 11 patients at 12 months. Neointimal coverage rates were similar between the two groups based on OCT measurements. The neointimal thickness of BP-EES was significantly thicker at the 12th month than at the 4th month, whereas the neointimal thickness of BVS did not change between the measurements taken at the 4th and 12th month. Existence of intra-stent thrombus was significantly higher in the BVS group, compared to the BP-EES group. On the other hand, CAS revealed that red-thrombi and yellow-plaque were more frequently observed in BVS at 4 months and up to 12-month follow-ups than in BP-EES. These findings suggested that the evidence of instability remained up to 12 months in the vascular healing with BVS, compared to that with BP-EES. Vascular healing of the stented wall was recognized at the very early phase after BP-EES implantation. However, vascular healing with BVS was still incomplete after 12 months.Keywords
Funding Information
- Boston Scientific Corporation
This publication has 22 references indexed in Scilit:
- Primary Endpoint Results of the EVOLVE TrialJACC, 2012
- From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?European Heart Journal, 2011
- The Pathology of Neoatherosclerosis in Human Coronary ImplantsJACC, 2011
- Heterogeneous Arterial Healing in Patients Following Paclitaxel-Eluting Stent ImplantationJACC: Cardiovascular Interventions, 2009
- Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative StressJACC: Cardiovascular Interventions, 2009
- Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent ImplantationCirculation, 2007
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Incomplete Neointimal Coverage of Sirolimus-Eluting StentsJACC, 2006
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- Angioscopic coronary macromorphology in patients with acute coronary disordersThe Lancet, 1991